A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects With Chronic Kidney Disease-associated Pruritus (CKD-aP)
Latest Information Update: 19 Mar 2025
At a glance
- Drugs MC2-25 (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Acronyms ITCHINESS
- Sponsors MC2 Therapeutics
Most Recent Events
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 07 Dec 2023 According to a MC2 Therapeutics media release, top-line results from the study are expected in Q2 2024.
- 07 Dec 2023 According to a MC2 Therapeutics media release, enrollment has been completed in this study.